197 related articles for article (PubMed ID: 30638304)
1. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers.
Wittenburg LA; Weishaar K; Ramirez D; Gustafson DL
Vet Comp Oncol; 2019 Jun; 17(2):147-154. PubMed ID: 30638304
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
3. Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.
Wittenburg LA; Thamm DH; Gustafson DL
Vet Comp Oncol; 2014 Jun; 12(2):114-9. PubMed ID: 22747489
[TBL] [Abstract][Full Text] [Related]
4. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
[TBL] [Abstract][Full Text] [Related]
5. Investigation of hepatobiliary disposition of doxorubicin following intrahepatic delivery of different dosage forms.
Lilienberg E; Ebeling Barbier C; Nyman R; Hedeland M; Bondesson U; Axén N; Lennernäs H
Mol Pharm; 2014 Jan; 11(1):131-44. PubMed ID: 24171458
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma.
Lu Y; Pan J; Zhu X; Zhang S; Liu C; Sun J; Li Y; Chen S; Huang J; Cao C; Wang Y; Li Y; Liu T
BMC Pharmacol Toxicol; 2021 Sep; 22(1):48. PubMed ID: 34488896
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
Barpe DR; Rosa DD; Froehlich PE
Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
[TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a 0.75 × 10
Bisson JL; Fournier Q; Johnston E; Handel I; Bavcar S
Vet Comp Oncol; 2020 Sep; 18(3):258-268. PubMed ID: 31600416
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin.
Hallman BE; Hauck ML; Williams LE; Hess PR; Suter SE
J Vet Intern Med; 2019 Mar; 33(2):783-791. PubMed ID: 30697816
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of two different delivery regimens of doxorubicin in isolated hyperthermic limb perfusion.
Pfeiffer T; Krause U; Thome U; Skorzek M; Scheulen ME
Eur J Surg Oncol; 1995 Oct; 21(5):551-4. PubMed ID: 7589605
[TBL] [Abstract][Full Text] [Related]
13. Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.
Fournier Q; Serra JC; Handel I; Lawrence J
J Vet Intern Med; 2018 Jan; 32(1):384-393. PubMed ID: 29205493
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and pharmacokinetic aspects of iodo-doxorubicin.
Mross K; Mayer U; Zeller W; Becker K; Hossfeld DK
Oncol Res; 1992; 4(6):227-31. PubMed ID: 1421615
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.
Piscitelli SC; Rodvold KA; Rushing DA; Tewksbury DA
Clin Pharmacol Ther; 1993 May; 53(5):555-61. PubMed ID: 8387903
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection.
Ren S; Li C; Dai Y; Li N; Wang X; Tian F; Zhou S; Qiu Z; Lu Y; Zhao D; Chen X; Chen D
J Pharm Pharmacol; 2014 Sep; 66(9):1231-9. PubMed ID: 24716458
[TBL] [Abstract][Full Text] [Related]
18. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
Averbach A; Stuart OA; Chang D; Sugarbaker PH
Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic evaluation of intraperitoneal doxorubicin in rats.
Nagai K; Nogami S; Egusa H; Konishi H
Pharmazie; 2014 Feb; 69(2):125-7. PubMed ID: 24640601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
